https://mindmedicinelaw.com/briefing/neuroimaging-predictors-of-ketamine-response-in-treatment-20260715-129Psychedelic Research Journalen2026-04-24T05:16:20.866988+00:00Neuroimaging Predictors of Ketamine Response in Treatmentneuroimaging, ketamine response, personalized therapy, psychedelic-assisted therapy, biomarkers, clinical practicehttps://mindmedicinelaw.com/briefing/dea-schedules-mdmb-4en-pinaca-as-schedule-i-substance-20260424-170Psychedelic Research Journalen2026-04-24T15:06:19.469792+00:00DEA Schedules MDMB-4en-PINACA as Schedule I SubstanceMDMB-4en-PINACA, DEA, Schedule I, synthetic cannabinoids, Controlled Substances Act, drug policy, research restrictions, regulatory controls, international treaties, public health riskshttps://mindmedicinelaw.com/briefing/psyence-s-phase-iib-trial-for-npx-5-in-cancer-patients-20260423-156Psychedelic Research Journalen2026-04-24T05:16:30.936341+00:00Psyence's Phase IIb Trial for NPX-5 in Cancer Patientspsilocybin, cancer treatment, clinical trial, Psyence Biomedical, NPX-5, psychedelic therapy, serotonin receptors, FDA approval, symptom management, Phase IIb trialhttps://mindmedicinelaw.com/briefing/doj-reschedules-marijuana-implications-for-psychedelics-20260423-158Psychedelic Research Journalen2026-04-24T05:16:11.196699+00:00DOJ Reschedules Marijuana: Implications for PsychedelicsDOJ marijuana rescheduling, federal drug policy, psychedelic research, cannabis industry, DEA, FDA, Controlled Substances Act, psilocybin, MDMA, drug policy reformhttps://mindmedicinelaw.com/briefing/trump-orders-fda-to-expedite-psychedelic-drug-reviews-20260423-155Psychedelic Research Journalen2026-04-24T05:15:44.483994+00:00Trump Orders FDA to Expedite Psychedelic Drug ReviewsFDA, psychedelic drug reviews, Trump directive, psychedelic therapies, drug approval process, medical use of psychedelics, policy shift, clinical trials, therapeutic potential, federal policyhttps://mindmedicinelaw.com/briefing/psilocybin-and-alternatives-for-treatment-resistant-depression-20260422-44Psychedelic Research Journalen2026-04-24T15:06:52.426178+00:00Psilocybin and Alternatives for Treatment-Resistant Depressiontreatment-resistant depression, psilocybin, ketamine, esketamine, vagus nerve stimulation, alternative treatments, clinical trials, mental health, psychedelic therapy, depression treatmenthttps://mindmedicinelaw.com/briefing/psilocybin-s-role-in-treating-depression-and-anxiety-a-review-20260422-207Psychedelic Research Journalen2026-04-24T15:06:37.610098+00:00Psilocybin's Role in Treating Depression and Anxiety: A Reviewpsilocybin, depression treatment, anxiety therapy, neuroplasticity, clinical trials, mental health, serotonergic agonist, treatment-resistant, PRISMA guidelines, brain networkshttps://mindmedicinelaw.com/briefing/kat-pilot-study-in-indigenous-health-services-in-canada-20260422-90Psychedelic Research Journalen2026-04-24T05:16:40.479850+00:00KAT Pilot Study in Indigenous Health Services in Canadaketamine-assisted therapy, Indigenous healthcare, cultural adaptation, mental health, Canada, pilot study, Siksika First Nation, psychedelic therapy, culturally responsive interventions, mental health inequitieshttps://mindmedicinelaw.com/briefing/synaptic-density-and-depression-in-parkinson-s-new-insights-20260421-254Psychedelic Research Journalen2026-04-24T15:07:31.092220+00:00Synaptic Density and Depression in Parkinson's: New Insightssynaptic density, Parkinson's disease, depression, neurobiology, PET imaging, synaptic plasticity, mood circuitry, clinical trials, mental health, radiotracerhttps://mindmedicinelaw.com/briefing/psilocybin-therapy-for-depression-meta-analysis-insights-20260421-80Psychedelic Research Journalen2026-04-24T15:07:17.557871+00:00Psilocybin Therapy for Depression: Meta-Analysis Insightspsilocybin therapy, depression treatment, meta-analysis, randomized controlled trials, psychedelic research, clinical trials, methodological limitations, phase 3 trials, mental health, evidence-based medicinehttps://mindmedicinelaw.com/briefing/esketamine-s-role-in-postoperative-care-for-elderly-crc-patients-20260421-93Psychedelic Research Journalen2026-04-24T15:07:04.486076+00:00Esketamine's Role in Postoperative Care for Elderly CRC Patientsesketamine, postoperative depression, elderly patients, colorectal cancer, sufentanil, randomized controlled trial, psychological benefits, enhanced recovery protocols, NMDA receptor antagonist, patient satisfactionhttps://mindmedicinelaw.com/briefing/trump-s-executive-order-alters-psychedelic-drug-policy-20260418-154Psychedelic Research Journalen2026-04-24T05:16:00.756253+00:00Trump's Executive Order Alters Psychedelic Drug Policypsychedelic drugs, executive order, Trump, federal policy, research opportunities, regulatory oversight, market dynamics, psilocybin, MDMA, clinical trials